1887

Abstract

The selection and characterization of a set of mouse mAbs against high-risk human papillomavirus (HPV) E7 oncoprotein and the development of protocols for immunocytochemistry (ICC) are described here. A large number of antibodies raised towards HPV16 and 18 E7 were tested for high-risk specificity by ELISA using a panel of HPV E7 proteins. Antibodies detecting low-risk E7 were discarded, resulting in 38 high-risk HPV E7-specific antibodies. The corresponding epitopes were mapped using overlapping HPV E7 fragments displayed on phage particles. Functionality in ICC against formalin-fixed cervical cancer cell lines was demonstrated for ten mAbs; their high-risk specificity was confirmed by Western blot analysis and ICC on transiently transformed cells expressing high- or low-risk HPV E7. These mAbs were specific for one or several of the high-risk strains HPV16, 18, 31, 35 and 45. Specific E7 staining of liquid-based cytology (LBC) samples was demonstrated for seven mAbs and optimized protocols were established. The E716-41 and E718-79 mAbs demonstrated particularly strong and specific staining of cells stored in LBC fluid for at least 6 months. It is proposed that the high-risk HPV E7 staining protocols established in this study may have the potential to be included in a complementary test for the detection and identification of malignantly transformed cells, in for example atypical squamous cells of undetermined significance samples.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.034884-0
2012-02-01
2019-10-23
Loading full text...

Full text loading...

/deliver/fulltext/jgv/93/2/356.html?itemId=/content/journal/jgv/10.1099/vir.0.034884-0&mimeType=html&fmt=ahah

References

  1. Arbyn M. , Bergeron C. , Klinkhamer P. , Martin-Hirsch P. , Siebers A. G. , Bulten J. . ( 2008; ). Liquid compared with conventional cervical cytology: a systematic review and meta-analysis. . Obstet Gynecol 111:, 167–177. [CrossRef] [PubMed]
    [Google Scholar]
  2. Bernard H. U. , Burk R. D. , Chen Z. , van Doorslaer K. , Hausen H. , de Villiers E. M. . ( 2010; ). Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. . Virology 401:, 70–79. [CrossRef] [PubMed]
    [Google Scholar]
  3. Bonnycastle L. L. C. , Menendez A. , Scott J. K. . ( 2001; ). General Phage Methods. . In Phage Display: a Laboratory Manual, pp. 15.1–15.30. Edited by Barbas C. F. , Burton D. R. , Scott J. K. , Silverman G. J. . . Cold Spring Harbour, New York:: Cold Spring Harbour Laboratory;.
    [Google Scholar]
  4. Bouvard V. , Baan R. , Straif K. , Grosse Y. , Secretan B. , El Ghissassi F. , Benbrahim-Tallaa L. , Guha N. , Freeman C. . & other authors ( 2009; ). A review of human carcinogens–Part B: biological agents. . Lancet Oncol 10:, 321–322. [CrossRef] [PubMed]
    [Google Scholar]
  5. Castle P. E. . ( 2008; ). Invited commentary: is monitoring of human papillomavirus infection for viral persistence ready for use in cervical cancer screening?. Am J Epidemiol 168:, 138–144, discussion 145–148. [CrossRef] [PubMed]
    [Google Scholar]
  6. de Sanjosé S. , Diaz M. , Castellsagué X. , Clifford G. , Bruni L. , Muñoz N. , Bosch F. X. . ( 2007; ). Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. . Lancet Infect Dis 7:, 453–459. [CrossRef] [PubMed]
    [Google Scholar]
  7. de Sanjosé S. , Quint W. G. , Alemany L. , Geraets D. T. , Klaustermeier J. E. , Lloveras B. , Tous S. , Felix A. , Bravo L. E. . & other authors ( 2010; ). Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. . Lancet Oncol 11:, 1048–1056. [CrossRef] [PubMed]
    [Google Scholar]
  8. de St Groth S. F. , Scheidegger D. . ( 1980; ). Production of monoclonal antibodies: strategy and tactics. . J Immunol Methods 35:, 1–21. [CrossRef] [PubMed]
    [Google Scholar]
  9. Doorbar J. . ( 2006; ). Molecular biology of human papillomavirus infection and cervical cancer. . Clin Sci (Lond) 110:, 525–541. [CrossRef] [PubMed]
    [Google Scholar]
  10. Jeon J. H. , Shin D. M. , Cho S. Y. , Song K. Y. , Park N. H. , Kang H. S. , Kim Y. D. , Kim I. G. . ( 2007; ). Immunocytochemical detection of HPV16 E7 in cervical smear. . Exp Mol Med 39:, 621–628.[PubMed] [CrossRef]
    [Google Scholar]
  11. Kitchener H. C. , Castle P. E. , Cox J. T. . ( 2006; ). Chapter 7: achievements and limitations of cervical cytology screening. . Vaccine 24: (Suppl. 3), S63–S70. [CrossRef] [PubMed]
    [Google Scholar]
  12. Koutsky L. . ( 1997; ). Epidemiology of genital human papillomavirus infection. . Am J Med 102: (Suppl. 1), 3–8. [CrossRef] [PubMed]
    [Google Scholar]
  13. Lidqvist M. , Nilsson O. , Holmgren J. , Hall C. , Fermér C. . ( 2008; ). Phage display for site-specific immunization and characterization of high-risk human papillomavirus specific E7 monoclonal antibodies. . J Immunol Methods 337:, 88–96. [CrossRef] [PubMed]
    [Google Scholar]
  14. Schiffman M. , Castle P. E. . ( 2003; ). Human papillomavirus: epidemiology and public health. . Arch Pathol Lab Med 127:, 930–934.[PubMed]
    [Google Scholar]
  15. Schiffman M. , Wentzensen N. , Wacholder S. , Kinney W. , Gage J. C. , Castle P. E. . ( 2011; ). Human papillomavirus testing in the prevention of cervical cancer. . J Natl Cancer Inst 103:, 368–383. [CrossRef] [PubMed]
    [Google Scholar]
  16. van der Loos C. M. . ( 2007; ). A focus on fixation. . Biotech Histochem 82:, 141–154. [CrossRef] [PubMed]
    [Google Scholar]
  17. von Knebel Doeberitz M. . ( 2002; ). New markers for cervical dysplasia to visualise the genomic chaos created by aberrant oncogenic papillomavirus infections. . Eur J Cancer 38:, 2229–2242. [CrossRef] [PubMed]
    [Google Scholar]
  18. Walboomers J. M. M. , Jacobs M. V. , Manos M. M. , Bosch F. X. , Kummer J. A. , Shah K. V. , Snijders P. J. F. , Peto J. , Meijer C. J. L. M. , Muñoz N. . ( 1999; ). Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. . J Pathol 189:, 12–19. [CrossRef] [PubMed]
    [Google Scholar]
  19. WHO/ICO Information Centre on HPV and Cervical Cancer ( 2007; ). HPV and cervical cancer in the 2007 report. . Vaccine 25: (Suppl. 3), C1–C230.[PubMed] [CrossRef]
    [Google Scholar]
  20. zur Hausen H. . ( 1996; ). Papillomavirus infections–a major cause of human cancers. . Biochim Biophys Acta 1288:, F55–F78.[PubMed]
    [Google Scholar]
  21. zur Hausen H. . ( 2002; ). Papillomaviruses and cancer: from basic studies to clinical application. . Nat Rev Cancer 2:, 342–350. [CrossRef] [PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.034884-0
Loading
/content/journal/jgv/10.1099/vir.0.034884-0
Loading

Data & Media loading...

Supplements

Supplementary Table 

PDF

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error